M
Martin von Bergen
Researcher at Helmholtz Centre for Environmental Research - UFZ
Publications - 395
Citations - 19405
Martin von Bergen is an academic researcher from Helmholtz Centre for Environmental Research - UFZ. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 58, co-authored 346 publications receiving 15305 citations. Previous affiliations of Martin von Bergen include Max Planck Society & Leipzig University.
Papers
More filters
Journal ArticleDOI
Identification of harmless and pathogenic algae of the genus Prototheca by MALDI-MS.
Martin von Bergen,Angelika Eidner,Frank Schmidt,Jayaseelan Murugaiyan,Henry Wirth,Henry Wirth,Hans Binder,Thomas Maier,Uwe Roesler,Uwe Roesler +9 more
TL;DR: As a result, pathogenic and nonpathogenic species from the genus Prototheca can be identified, with possible consequences for clinical diagnostics by MALDI‐typing.
Journal ArticleDOI
Concentration–response concept in ecotoxicoproteomics: Effects of different phenanthrene concentrations to the zebrafish (Danio rerio) embryo proteome
Ulrike Gündel,Stefan Kalkhof,Dimitar Zitzkat,Martin von Bergen,Rolf Altenburger,Eberhard Küster +5 more
TL;DR: The utility and several benefits using a concentration-response approach in proteomics studies could be shown including knowledge about and the ability to model concentration dependent dynamics of molecular endpoints and to help selecting the most promising protein spots for further investigations such as protein identification and biomarker studies.
Journal ArticleDOI
Methylamine as a nitrogen source for microorganisms from a coastal marine environment
Martin Taubert,Martin Taubert,Carolina Grob,Alexandra M. Howat,Oliver J. Burns,Jennifer Pratscher,Nico Jehmlich,Martin von Bergen,Hans H. Richnow,Yin Chen,J. Colin Murrell +10 more
TL;DR: Stable isotope probing was used to identify microorganisms from a coastal environment that assimilate nitrogen from methylamine, and both bacteria identified used the γ‐glutamyl‐methylamide pathway, found in both methylotrophs and non‐methylotrophic microorganisms, to metabolize methYlamine.
Patent
Treating neurodegenerative conditions
TL;DR: In this article, the use of compounds capable of inhibiting protein aggregate formation and capable of depolymerising protein aggregates for the preparation of a pharmiaceutical composition for treating neurodegenerative conditions such as Alzheimer disease was discussed.
Journal ArticleDOI
Enzymes involved in the anaerobic degradation of meta-substituted halobenzoates
Kevin Kuntze,Patrick Kiefer,Sven Baumann,Jana Seifert,Martin von Bergen,Julia A. Vorholt,Matthias Boll +6 more
TL;DR: It appears that the presence of a halobenzoate‐specific carboxylic acid CoA ligase rather than a specific reductive dehalogenase governs whether an aromatic compound degrading anaerobe is capable of metabolizing halobanzoates.